217 related articles for article (PubMed ID: 11961894)
1. [Biopharmaceutical considerations of dissolution testing used as a prognostic tool for oral drug adsorption].
Antal I
Acta Pharm Hung; 2001 Oct; 71(3):280-8. PubMed ID: 11961894
[TBL] [Abstract][Full Text] [Related]
2. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
4. In vitro - in vivo correlation: from theory to applications.
Emami J
J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
[TBL] [Abstract][Full Text] [Related]
5. In vitro models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
[TBL] [Abstract][Full Text] [Related]
6. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Tsume Y; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
[TBL] [Abstract][Full Text] [Related]
7. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
8. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
9. Simulating the postprandial stomach: physiological considerations for dissolution and release testing.
Koziolek M; Garbacz G; Neumann M; Weitschies W
Mol Pharm; 2013 May; 10(5):1610-22. PubMed ID: 23506381
[TBL] [Abstract][Full Text] [Related]
10. The use of drug metabolism for prediction of intestinal permeability (dagger).
Chen ML; Yu L
Mol Pharm; 2009; 6(1):74-81. PubMed ID: 19132929
[TBL] [Abstract][Full Text] [Related]
11. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
Lennernäs H; Abrahamsson B
J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
[TBL] [Abstract][Full Text] [Related]
12. Biopharmaceutical classification based on solubility and dissolution: a reappraisal of criteria for hypothesis models in the light of the experimental observations.
Charkoftaki G; Dokoumetzidis A; Valsami G; Macheras P
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):168-72. PubMed ID: 20030634
[TBL] [Abstract][Full Text] [Related]
13. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
[TBL] [Abstract][Full Text] [Related]
14. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
Heigoldt U; Sommer F; Daniels R; Wagner KG
Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
[TBL] [Abstract][Full Text] [Related]
15. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective.
Chen ML
Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051
[TBL] [Abstract][Full Text] [Related]
16. Prediction of human pharmacokinetics--gastrointestinal absorption.
Fagerholm U
J Pharm Pharmacol; 2007 Jul; 59(7):905-16. PubMed ID: 17637184
[TBL] [Abstract][Full Text] [Related]
17. Dissolution testing of oral modified-release dosage forms.
Garbacz G; Klein S
J Pharm Pharmacol; 2012 Jul; 64(7):944-68. PubMed ID: 22686342
[TBL] [Abstract][Full Text] [Related]
18. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
19. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
20. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
Pouton CW
Eur J Pharm Sci; 2006 Nov; 29(3-4):278-87. PubMed ID: 16815001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]